Dr. Tanya Shree, MD, PHD

Targeting T regulatory type 1 cells for cancer immunotherapy

Regulatory cells can hinder successful cancer immunotherapy. We found regulatory Tr1 cells, usually seen in autoimmune diseases, in lymphoma tumors. Our previous work suggests the drug ibrutinib might reduce Tr1s. We will study how ibrutinib blocks Tr1s and seek new strategies for Tr1 blocking so we can improve immunotherapy results.